[Psychedelics and pyschodelic-associated psychotherapies - Who is PAP for after all?]
Abstract
Psychedelic drugs, historically recognized for their effects on perception, cognition, and emotion, are entering their renaissance, as a growing body of both preclinical and clinical evidence supports their potential for the treatment - mostly as an adjunct to psychotherapy, i.e., psychedelic-assisted psychotherapy (PAP) - of various psychiatric disorders. The recent approval of lysergic acid diethylamide (LSD) for generalized anxiety disorder, as well as that of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder and psilocybin for depression, suggests a new era in psychiatry. However, numerous questions remain unanswered, including how exactly PAP works. Here, we aimed to review the latest results of clinical trials and to summarize current knowledge on psychedelics, focusing on their use in psychiatry while addressing limitations and challenges to be faced in the future. Keywords: psychedelic; psilocybin; LSD; MDMA; MDMA-AT; psychedelic-assisted psychotherapy; PAP; PAT.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.